lipotropic therapy is not an FDA-approved drug for treating, curing, or preventing any disease
Lipolysis Enhancement and Lipogenesis Inhibition In obese Zucker rats, daily oral administration of AOD9604 significantly increased lipolytic activity in adipose tissue compared to controls, establishing direct adipocyte-level lipolysis stimulation as a key mechanism of action in pre-clinical models
law, compounding may occur through patient-specific prescriptions (503A pharmacies) or by FDA-registered outsourcing facilities (503B), and is generally permitted only when there is a legitimate clinical need or drug shortage
Injury Duration: Acute injuries less than 6 months old consistently respond better than chronic conditions
If you have any questions, please call 1-203-348-8805 How quickly do MOTS-c results appear
CagriSema's NDA was filed with FDA in December 2025